Author for correspondence: Chang-Qing Xu, Department of Pathophysiology, Harbin Medical University, Harbin150086, China (fax +86 451 87503325, e-mail [email protected]).

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Abstract: Polyamines (putrescine, spermidine and spermine) are essential for cell growth and differentiation. Nitric oxide exhibits antihypertrophic functions and inhibits cardiac remodelling. However, the metabolism of polyamines and the potential interactions with nitric oxide in cardiac hypertrophy remain unclear. We randomly divided Wistar rats into four treatment groups: controls, isoproterenol (ISO), ISO and l-arginine, and l-arginine. Isoproterenol (5 mg/kg/day, subcutaneously) and/or l-arginine (800 mg/kg/day, intraperitoneally) was administered once daily for 7 days. The expression of atrial natriuretic peptide mRNA was determined by reverse transcription–polymerase chain reaction, and fibrogenesis of heart was assessed by Van Gieson staining. Polyamines were measured with high-performance liquid chromatography, and plasma nitric oxide content and lactate dehydrogenase (LDH) activity were determined with a spectrophotometer. The expression levels of ornithine decarboxylase, spermidine/spermine N1-acetyltransferase (SSAT), endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) were analysed by Western blot. Heart-to-body weight ratio, left ventricle-to-body weight ratio, atrial natriuretic peptide mRNA expression, collagen fibres and LDH activity were elevated, both ornithine decarboxylase and SSAT proteins were up-regulated, and total polyamines were increased in the group treated with ISO. Additionally, the expression of iNOS was up-regulated, eNOS was down-regulated, and nitric oxide levels were low. Notably, cotreatment with l-arginine reversed most of these changes except for SSAT expression, which was further up-regulated. We propose that increased polyamines and decreased nitric oxide are involved in cardiac hypertrophy induced by ISO and suggest that l-arginine pre-treatment can attenuate cardiac hypertrophy through the regulation of key enzymes of the polyamine and nitric oxide pathways.

References

1 Bueno OF, Molkentin JD. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 2002; 91: 776–81.
10.1161/01.RES.0000038488.38975.1A
CAS PubMed Web of Science® Google Scholar
2 Friddle CJ, Koga T, Rubin EM, Bristow J. Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. Proc Natl Acad Sci USA 2000; 97: 6745–50.
10.1073/pnas.100127897
CAS PubMed Web of Science® Google Scholar
3 Liao Y, Asakura M, Takashima S, Ogai A, Asano Y, Shintani Y et al . Celiprolol, a vasodilatory β-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 2004; 110: 692–9.
10.1161/01.CIR.0000137831.08683.E1
CAS PubMed Web of Science® Google Scholar
4 Böger RH, Ron ES. l-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev 2005; 10: 14–23.
PubMed Web of Science® Google Scholar
5 Ozaki M, Kawashima S, Yamashita T, Hirase T, Ohashi Y, Inoue N et al . Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion. Circ J 2002; 66: 851–6.
10.1253/circj.66.851
CAS PubMed Web of Science® Google Scholar
6 Satriano J. Arginine pathways and the inflammatory response: interregulation of nitric oxide and polyamines: review article. Amino Acids 2004; 26: 321–9.
10.1007/s00726-004-0078-4
CAS PubMed Web of Science® Google Scholar
7 Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, Del Soldato P. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 2001; 98: 74202–8.
10.1073/pnas.071054698
Web of Science® Google Scholar
8 Wallace JL, Ignarro LJ, Fiorucci S. Potential cardioprotective actions of no-releasing aspirin. Nat Rev Drug Discov 2002; 5: 375–82.
10.1038/nrd794
CAS Web of Science® Google Scholar
9 Muhling J, Engel J, Halabi M, Muller M, Fuchs M, Krull M et al . Nitric oxide and polyamine pathways-dependent modulation of neutrophil free amino- and α-keto acide profiles or host defense capability. Amino Acids 2006; 31: 11–26.
10.1007/s00726-006-0273-6
CAS PubMed Web of Science® Google Scholar
10 Gallego M, Espina L, Vegas L, Echevarria E, Iriarte MM, Casis O. Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats. Pharmacol Res 2001; 44: 311–5.
10.1006/phrs.2001.0865
CAS PubMed Web of Science® Google Scholar
11 Balakumar P, Singh M. The possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats. Basic Clin Pharmacol Toxicol 2006; 99: 418–24.
10.1111/j.1742-7843.2006.pto_569.x
CAS PubMed Web of Science® Google Scholar
12 Uhal BD, Zhang H, Abdul-Hafez A, Shu R, Li X. Amiodarone induces angiotensinogen gene expression in lung alveolar epithelial cells through activation protein-1. Basic Clin Pharmacol Toxicol 2007; 100: 59–66.
10.1111/j.1742-7843.2007.00006.x
CAS PubMed Web of Science® Google Scholar
13 Zhao YJ, Xu CQ, Zhang WH, Zhang L, Bian SL, Huang Q et al . Role of polyamines in myocardial ischemia/reperfusion injury and their interactions with nitric oxide. Eur J Pharmacol 2007; 562: 236–46.
10.1016/j.ejphar.2007.01.096
CAS PubMed Web of Science® Google Scholar
14 Maiti S, Chen X, Chen G. All-trans retinoic acid induction of sulfotransferases. Basic Clin Pharmacol Toxicol 2005; 96: 44–53.
10.1111/j.1742-7843.2005.pto960107.x
CAS PubMed Web of Science® Google Scholar
15 Ibrahim J, Schachter M, Hughes AD, Sever PS. Role of polyamines in hypertension induced by angiotensin II. Cardiovasc Res 1995; 29: 50–6.
10.1016/0008-6363(96)88546-4
CAS PubMed Web of Science® Google Scholar
16 Lipke DW, Newman PS, Tofiq S, Guo H, Arcot SS, Aziz SM et al . Multiple polyamine regulatory pathways control compensatory cardiovascular hypertrophy in coarctation hypertension. Clin Exp Hypertens 1997; 19: 269–95.
10.3109/10641969709080819
CAS PubMed Web of Science® Google Scholar
17 Shantz LM, Feith DJ, Pegg AE. Targeted overexpression of ornithine decarboxylase enhances beta-adrenergic agonist-induced cardiac hypertrophy. Biochem J 2001; 358: 25–32.
10.1042/bj3580025
CAS PubMed Web of Science® Google Scholar
18 Karupiah G, Xie QW, Buller ML, Nathan C, Duarte C, MacMicking JD. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 1993; 26: 14445–8.
Google Scholar
19 Xia Y, Zweier JL. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci USA 1997; 94: 6954–8.
10.1073/pnas.94.13.6954
CAS PubMed Web of Science® Google Scholar
20 Förstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I et al . Nitric oxide synthase isozymes: characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 1121–31.
10.1161/01.HYP.23.6.1121
PubMed Web of Science® Google Scholar
21 Brede M, Roell W, Ritter O, Esmann F, Jahns R, Haase A et al . Cardiac hypertrophy is associated with decreased eNOS expression in angiotensin AT2 receptor-deficient mice. Hypertension 2003; 42: 1177–82.
10.1161/01.HYP.0000100445.80029.8E
CAS PubMed Web of Science® Google Scholar
22 Chen Y, Hou M, Li Y, Traverse JH, Zhang P, Salvemini D et al . Increased superoxide production causes coronary endothelial dysfunction and depressed oxygen consumption in the failing heart. Am J Physiol Heart Circ Physiol 2005; 288: H133–41.
10.1152/ajpheart.00851.2003
CAS PubMed Web of Science® Google Scholar
23 Hare JM. Nitroso-redox balance in the cardiovascular system. N Engl J Med 2004; 351: 2112–4.
10.1056/NEJMe048269
CAS PubMed Web of Science® Google Scholar
24 Balakumar P, Singh AP, Ganti SS, Krishan P, Ramasamy S, Singh M. Resident cardiac mast cells: are they the major culprit in the pathogenesis of cardiac hypertrophy? Basic Clin Pharmacol Toxicol 2008; 102: 5–9.
10.1111/j.1742-7843.2007.00147.x
CAS PubMed Web of Science® Google Scholar
25 Harada S, Nakata T, Oguni A, Kido H, Hatta T, Fukuyama R et al . Contrasting effects of angiotensin type 1 and 2 receptors on nitric oxide release under pressure. Hypertens Res 2002; 25: 779–88.
10.1291/hypres.25.779
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume103, Issue2

August 2008

Pages 124-130

l-Arginine Inhibits Isoproterenol-Induced Cardiac Hypertrophy through Nitric Oxide and Polyamine Pathways

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

l-Arginine Inhibits Isoproterenol-Induced Cardiac Hypertrophy through Nitric Oxide and Polyamine Pathways

Abstract

References

Citing Literature

References

Related

Information